The present invention comprises methods and compositions for the reductionof oxalate in humans. For example, the invention provides methods and compositionsfor the delivery of one or more oxalate-reducing enzymes embedded in particlecompositions. The compositions of the present invention are suitable in methodsof treatment or prevention of oxalate-related conditions including, but notlimited to, hyperoxaluria, absorptive hyperoxaluria, enteric hyperoxaluria,primary hyperoxaluria, idiopathic calcium oxalate kidney stone disease (urolithiasis),vulvodynia, oxalosis associated with end-stage renal disease, cardiac conductancedisorders, inflammatory bowel disease, Crohn's disease, ulcerativecolitis, and patients who have undergone gastrointestinal surgery and bariatricsurgery (surgery for obesity), and/or who have undergone antibiotic treatment.
